Search clinical trials for: Tislelizumab plus Bevacizumab

Total 7541 results

Henan Provincial People's Hospital

Not yet recruiting

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
BeiGene

Completed

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Carcinoma, Hepatocellular | Gastric/Gastroesophageal Junction Cancer

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

China
Henan Provincial People's Hospital

Recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Oligodendroglioma

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Cervical Cancer
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Lei Li

Recruiting

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1

China
Chinese PLA General Hospital

Recruiting

CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA

Advanced Gastroesophageal Adenocarcinoma | First-line Therapy | PDL1 CPS < 5

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Bevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutated

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
BeiGene

Completed

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China, Taiwan
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Second Affiliated Hospital of Nanchang University
Zhejiang University

Not yet recruiting

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Glioblastoma
Fujian Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
Tae Won Kim

Recruiting

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (DYNAMIC)

Hepatocellular Carcinoma

Korea, Republic of
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential Chemoradiation

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Fudan University

Active, not recruiting

Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Shanghai Gopherwood Biotech Co., Ltd.

Recruiting

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Malignant Solid Tumors

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Fudan University

Not yet recruiting

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study (TEMPLATE)

Triple Negative Breast Cancer

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
University College, London
BeiGene

Not yet recruiting

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)

Hodgkin Lymphoma
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Yonsei University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

HER2-positive Gastric Cancer

Korea, Republic of
Peking University Cancer Hospital & Institute

Recruiting

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Melanoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

China
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (CIRCUS)

Metastatic Colorectal Cancer

Italy

3

Subscribe